Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
8.17
+0.01 (0.12%)
At close: Mar 6, 2026, 4:00 PM EST
8.02
-0.15 (-1.84%)
After-hours: Mar 6, 2026, 6:58 PM EST
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 10 or 22.22% compared to the previous year.
Employees
55
Change (1Y)
10
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,361,455
Market Cap
544.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Allogene Therapeutics | 229 |
| Rigel Pharmaceuticals | 164 |
| Prothena Corporation | 163 |
| Alpha Tau Medical | 125 |
| Solid Biosciences | 100 |
| Ocugen | 95 |
| Verastem | 78 |
FULC News
- 1 day ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 9 days ago - Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion - Seeking Alpha
- 11 days ago - Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 11 days ago - Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 18 days ago - Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha